4yvx
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | ''' | + | ==Crystal struture of AKR1C3 complexed with glimepiride== |
| + | <StructureSection load='4yvx' size='340' side='right' caption='[[4yvx]], [[Resolution|resolution]] 2.30Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[4yvx]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YVX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4YVX FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GMR:3-ETHYL-4-METHYL-N-[2-(4-{[(CIS-4-METHYLCYCLOHEXYL)CARBAMOYL]SULFAMOYL}PHENYL)ETHYL]-2-OXO-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE'>GMR</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene></td></tr> | ||
| + | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4yvp|4yvp]], [[4yvv|4yvv]]</td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4yvx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4yvx OCA], [http://pdbe.org/4yvx PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4yvx RCSB], [http://www.ebi.ac.uk/pdbsum/4yvx PDBsum]</span></td></tr> | ||
| + | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/AK1C3_HUMAN AK1C3_HUMAN]] Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone. | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Recent epidemiological studies show conflicting data for the first-line anti-diabetic sulphonylureas drugs in treating cancer progression in type II diabetes patients. How sulphonylureas promote or diminish tumor growth is not fully understood. Here, we report that seven sulphonylureas exhibit different in vitro inhibition towards AKR1Cs (AKR1C1, AKR1C2, AKR1C3), which are critical steroid hormone metabolism enzymes that are related to prostate cancer, breast cancer and endometrial diseases. Interactions of the sulphonylureas and AKR1Cs were analyzed by X-ray crystallography. | ||
| - | + | In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis.,Zhao Y, Zheng X, Zhang H, Zhai J, Zhang L, Li C, Zeng K, Chen Y, Li Q, Hu X Chem Biol Interact. 2015 Oct 5;240:310-5. doi: 10.1016/j.cbi.2015.09.006. Epub, 2015 Sep 8. PMID:26362498<ref>PMID:26362498</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | <div class="pdbe-citations 4yvx" style="background-color:#fffaf0;"></div> | |
| - | [[Category: | + | == References == |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Hu, X]] | ||
[[Category: Zhang, H]] | [[Category: Zhang, H]] | ||
| + | [[Category: Zhao, Y]] | ||
[[Category: Zheng, X]] | [[Category: Zheng, X]] | ||
| - | [[Category: | + | [[Category: Akr1c3 inhibitor]] |
| - | [[Category: | + | [[Category: Oxidoreductase-oxidoreductase inhibitor complex]] |
Revision as of 04:34, 1 December 2015
Crystal struture of AKR1C3 complexed with glimepiride
| |||||||||||
